Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
|Articles|May 19, 2010
- Psychiatric Times Vol 27 No 5
- Volume 27
- Issue 5
Get the Bigger Therapeutic Picture
Advertisement
- Cochrane Central Register of Controlled Trials (CENTRAL) is a bibliographical database of controlled trials. This is an important resource because using MEDLINE alone will not yield all possible reports of controlled trials.
http://uscc.cochrane.org/en/newPage3.html . Accessed March 24, 2010.
- MedWatch is the FDA safety information and adverse reporting program.
http://www.fda.gov/safety/MedWatch/default.htm . Accessed March 24, 2010.
- The Carlat Psychiatry Report is a monthly newsletter that provides clinically relevant, unbiased information on psychiatric practice and psychotropic medications and openly discusses alternatives to psychopharmacological treatment.
http://www.thecarlatreport.com . Accessed March 24, 2010.
- PharmedOut is a physician-run project funded through the Attorney General Consumer and Prescriber Education grant program that “empowers physicians to identify and counter inappropriate pharmaceutical promotion practices. PharmedOut promotes evidence-based medicine by providing news, resources, and links to pharma-free CME courses.”
http://www.pharmedout.org . Accessed March 24, 2010.
Articles in this issue
over 16 years ago
Ethical Aspects of Self-Disclosure in Psychotherapyover 16 years ago
Introduction: Ethical Dilemmas Old and Newover 16 years ago
Undue Pharmaceutical Influence on Psychiatric Practiceover 16 years ago
A Psychiatrist’s Guitar Poemover 16 years ago
DSM5 and the Medicalization of Grief: Two Perspectivesover 16 years ago
Extraordinarily Ordinaryover 16 years ago
The Political Diagnosis: Psychiatry in the Service of the Lawover 16 years ago
The Fort Hood Aftermath-Army Accountability Review and Psychiatristsover 16 years ago
Memory Reconsolidation and What Albert Ellis Knew All AlongAdvertisement
Related to this article
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5